75.60
+1.54(+2.08%)
Currency In USD
Address
5820 Oberlin Drive
San Diego, CA 92121
United States of America
Phone
858-246-6240
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
April 29, 2022
| Name | Title | Pay | Year Born |
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & Chief Executive Officer | 0 | 1978 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer & Director | 0 | 1984 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 0 | 1969 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 0 | 1967 |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.